Inhibition of T lymphocyte activation by estramustine: Dose-dependent interference with IL-2 production and later proliferation events
- 30 April 1985
- journal article
- Published by Elsevier in Immunopharmacology
- Vol. 9 (2) , 65-71
- https://doi.org/10.1016/0162-3109(85)90001-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Clinical pharmacokinetics of estramustine phosphateUrology, 1984
- Cytotoxic properties of estramustine unrelated to alkylating and steroid constituentsUrology, 1984
- Effects of diethylstilbestrol and estramustine phosphate (estracyt) on natural killer cell activity and tumor susceptibility in male miceThe Prostate, 1984
- In vitro and in vivo effects of diethylstilbestrol and estramustine phosphate (estracyt®) on the mitogen responsiveness of human peripheral blood lymphocytesThe Prostate, 1982
- Effect of diethylstilbestrol and estramustine phosphate (estracyt®) on delayed hypersensitivity response to oxazolone in male miceThe Prostate, 1982
- Prostaglandin inhibition of T-cell proliferation is mediated at two levelsCellular Immunology, 1981
- Two distinct factors are required for induction of T-cell growthNature, 1980
- Monoclonal cytolytic T-cell lines.The Journal of Experimental Medicine, 1979
- Pilot Study on the Growth Inhibition by Estramustine Phosphate (Estracyt®) of Rat Mammary Tumours Sensitive and Insensitive to OestrogenActa Pharmacologica et Toxicologica, 1979
- T-T-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity.The Journal of Experimental Medicine, 1978